Summary This latest Pharmaceutical and Healthcare disease pipeline guide Male Infertility - Pipeline Review, H1 2020, provides an overview of the Male Infertility (Male Health) pipeline landscape.
Male infertility refers to a male’s inability to achieve a pregnancy in a fertile female. Male infertility is caused due to low sperm production, immobile sperm, or blockages that prevent the delivery of sperm. Symptoms include pain, swelling or a lump in the testicle area. Predisposing factors include smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes surgery and hormone replacement therapy.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Male Infertility - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 4, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Male Infertility (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Male Infertility (Male Health). - The pipeline guide reviews pipeline therapeutics for Male Infertility (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Male Infertility (Male Health) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Male Infertility (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Male Infertility (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Male Infertility (Male Health). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Male Infertility (Male Health) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Male Infertility Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Male Infertility Global Clinical Trials Review, H1, 2020" provides an overview of Male Infertility Clinical trials scenario.This report provides top line data relating to the clinical trials on Male Infertility. Report...
The Global Male Infertility Market size is expected to reach $3.2 billion by 2026, rising at a market growth of 7.6% CAGR during the forecast period. Male infertility is the inability of a male to cause pregnancy in a fertile female. A male’s fertility relies mainly on the quantity and quality of their sperms. If a man’s sperm count is small...
Male Infertility Market Research Report by Test (Computer-assisted Semen Analysis, DNA Fragmentation Technique, Microscopic Examination, Oxidative Stress Analysis, and Sperm Agglutination), by Treatment (Assisted Reproductive Technology and Medication) - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global...
189 pages •
By Global Industry Analysts
• Jul 2020
Global Kidney Stone Management Devices Market to Reach US$1.6 Billion by the Year 2027 Amid the COVID-19 crisis, the global market for Kidney Stone Management Devices estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.6 Billion by 2027, growing at a CAGR of 3% over the analysis period 2020-2027.Extracorporeal...
Overactive Bladder - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 2020, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape. Overactive bladder...
Congenital Heart Disease Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Congenital Heart Disease Global Clinical Trials Review, H1, 2020" provides an overview of Congenital Heart Disease Clinical trials scenario.This report provides top line data relating to the clinical...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.